Cosmos Health Inc. (NASDAQ:COSM – Get Free Report) CFO Georgios Terzis bought 168,135 shares of Cosmos Health stock in a transaction that occurred on Tuesday, June 16th. The stock was purchased at an average cost of $0.25 per share, for a total transaction of $42,033.75. Following the acquisition, the chief financial officer owned 2,235,398 shares of the company’s stock, valued at $558,849.50. This represents a 8.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Cosmos Health Stock Up 6.9%
NASDAQ:COSM traded up $0.02 during mid-day trading on Wednesday, hitting $0.27. The stock had a trading volume of 15,822,733 shares, compared to its average volume of 2,791,739. The stock has a 50-day simple moving average of $0.30 and a two-hundred day simple moving average of $0.39. The company has a market capitalization of $16.57 million, a PE ratio of -0.41 and a beta of 4.80. Cosmos Health Inc. has a twelve month low of $0.19 and a twelve month high of $1.32. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31.
Cosmos Health (NASDAQ:COSM – Get Free Report) last issued its earnings results on Thursday, May 21st. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.93 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. On average, equities research analysts anticipate that Cosmos Health Inc. will post -0.06 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Cosmos Health
Institutional Trading of Cosmos Health
Several hedge funds have recently added to or reduced their stakes in COSM. Renaissance Technologies LLC increased its stake in Cosmos Health by 16.7% in the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock valued at $124,000 after purchasing an additional 55,925 shares during the last quarter. Citadel Advisors LLC increased its stake in Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares during the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.
Cosmos Health Company Profile
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Featured Articles
- Five stocks we like better than Cosmos Health
- Draining the Tank: Big Oil Runs on Fumes
- Microsoft’s Xbox Problem Is Bigger Than a Console War
- Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
